MetaCap

Aktis Oncology Insider Trades

NASDAQ: AKTSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

18.15+0.41 (+2.31%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
9 · $114.31M
Sales
11 · $3.23M
Shares bought / sold
6.35M / 120.42K
Net activity
Net buying $111.1 million

Aktis Oncology insider activity

Over the last 12 months, Aktis Oncology insiders reported 43 transactions on SEC Form 4: 9 open-market purchases and 11 sales. Insiders bought $114.3 million and sold $3.2 million worth of stock, for net insider buying of $111.1 million. The largest seller was Czibere Akos, with $1.6 million in reported sales.

The most recent filing shows Czibere Akos (Chief Medical Officer) reporting a transaction in 12,500 shares at $4.95 on Sep 23, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put AKTS's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

AKTS insider transactions

Aktis Oncology insider transactions
DateInsiderTypeSharesValueFiling
Sep 23, 2026Czibere AkosChief Medical OfficerSale7,401$155.65KForm 4
Sep 23, 2026Czibere AkosChief Medical OfficerSale5,099$102.97KForm 4
Sep 23, 2026Czibere AkosChief Medical OfficerOption exercise12,500$61.88KForm 4
Jul 20, 2026Herrmann KenDirectorSale1,350$33.16KForm 4
Jul 20, 2026Herrmann KenDirectorSale3,506$86.12KForm 4
Jul 20, 2026Herrmann KenDirectorOption exercise1,350$2.58KForm 4
Jul 20, 2026Herrmann KenDirectorOption exercise3,506$280.48Form 4
Jul 17, 2026Herrmann KenDirectorSale3,065$77.26KForm 4
Jul 17, 2026Herrmann KenDirectorOption exercise3,065$245.20Form 4
Jul 8, 2026Ron-Bigger ShulamitChief Operating OfficerSale4,200$120.74KForm 4
Jul 8, 2026Ron-Bigger ShulamitChief Operating OfficerSale30,000$838.14KForm 4
Jul 8, 2026Ron-Bigger ShulamitChief Operating OfficerSale15,800$428.68KForm 4
Jul 8, 2026Ron-Bigger ShulamitChief Operating OfficerOption exercise50,000$183.00KForm 4
Jul 8, 2026Czibere AkosChief Medical OfficerSale4,371$125.48KForm 4
Jul 8, 2026Czibere AkosChief Medical OfficerSale30,829$861.74KForm 4
Jul 8, 2026Czibere AkosChief Medical OfficerSale14,800$401.48KForm 4
Jul 8, 2026Czibere AkosChief Medical OfficerOption exercise50,000$247.50KForm 4
Jan 12, 2026EcoR1 Capital, LLC & NODELMAN OLEGDirectorBuy144,443$2.60MForm 4
Jan 12, 2026EcoR1 Capital, LLC & NODELMAN OLEGDirectorBuy2,077,779$37.40MForm 4
Jan 12, 2026EcoR1 Capital, LLC & NODELMAN OLEGDirectorConversion128,506—Form 4
Jan 12, 2026EcoR1 Capital, LLC & NODELMAN OLEGDirectorConversion202,862—Form 4
Jan 12, 2026EcoR1 Capital, LLC & NODELMAN OLEGDirectorConversion2,270,879—Form 4
Jan 12, 2026Segal Lloyd MitchellDirectorConversion19,631—Form 4
Jan 12, 2026Kim Helen SusanDirectorBuy22,545$405.81KForm 4
Jan 12, 2026Kim Helen SusanDirectorConversion134,842—Form 4
Jan 12, 2026Kim Helen SusanDirectorBuy812,455$14.62MForm 4
Jan 12, 2026Kim Helen SusanDirectorConversion4,859,370—Form 4
Jan 12, 2026Vida Ventures II, LLC & VIDA VENTURES II-A, LLC10% OwnerBuy22,545$405.81KForm 4
Jan 12, 2026Vida Ventures II, LLC & VIDA VENTURES II-A, LLC10% OwnerConversion134,842—Form 4
Jan 12, 2026Vida Ventures II, LLC & VIDA VENTURES II-A, LLC10% OwnerBuy812,455$14.62MForm 4
Jan 12, 2026Vida Ventures II, LLC & VIDA VENTURES II-A, LLC10% OwnerConversion4,859,370—Form 4
Jan 12, 2026GADICKE ANSBERT & MPM ASSET MANAGEMENT LLC & Oncology Impact Private Investment Fund 2, L.P.10% OwnerBuy1,112,777$20.03MForm 4
Jan 12, 2026GADICKE ANSBERT & MPM ASSET MANAGEMENT LLC & Oncology Impact Private Investment Fund 2, L.P.10% OwnerConversion1,577,119—Form 4
Jan 12, 2026GADICKE ANSBERT & MPM ASSET MANAGEMENT LLC & Oncology Impact Private Investment Fund 2, L.P.10% OwnerConversion5,914,197—Form 4
Jan 12, 2026GADICKE ANSBERT & MPM ASSET MANAGEMENT LLC & Oncology Impact Private Investment Fund 2, L.P.10% OwnerConversion1,314,262—Form 4
Jan 12, 2026MPM BIOVENTURES 2018, L.P. & EVNIN LUKE & MPM BIOVENTURES 2018 (B), L.P. & MPM BioVentures 2018 LLC & MPM BioVentures 2018 GP LLC & MPM ASSET MANAGEMENT INVESTORS BV2018 LLC & MPM ONCOLOGY INNOVATIONS FUND LP & MPM Oncology Innovations Fund GP LLC10% OwnerBuy1,112,777$20.03MForm 4
Jan 12, 2026MPM BIOVENTURES 2018, L.P. & EVNIN LUKE & MPM BIOVENTURES 2018 (B), L.P. & MPM BioVentures 2018 LLC & MPM BioVentures 2018 GP LLC & MPM ASSET MANAGEMENT INVESTORS BV2018 LLC & MPM ONCOLOGY INNOVATIONS FUND LP & MPM Oncology Innovations Fund GP LLC10% OwnerConversion1,577,119—Form 4
Jan 12, 2026MPM BIOVENTURES 2018, L.P. & EVNIN LUKE & MPM BIOVENTURES 2018 (B), L.P. & MPM BioVentures 2018 LLC & MPM BioVentures 2018 GP LLC & MPM ASSET MANAGEMENT INVESTORS BV2018 LLC & MPM ONCOLOGY INNOVATIONS FUND LP & MPM Oncology Innovations Fund GP LLC10% OwnerConversion5,914,197—Form 4
Jan 12, 2026MPM BIOVENTURES 2018, L.P. & EVNIN LUKE & MPM BIOVENTURES 2018 (B), L.P. & MPM BioVentures 2018 LLC & MPM BioVentures 2018 GP LLC & MPM ASSET MANAGEMENT INVESTORS BV2018 LLC & MPM ONCOLOGY INNOVATIONS FUND LP & MPM Oncology Innovations Fund GP LLC10% OwnerConversion1,314,262—Form 4
Jan 12, 2026Foley ToddDirectorBuy232,870$4.19MForm 4
Jan 12, 2026Foley ToddDirectorConversion716,872—Form 4
Jan 12, 2026Foley ToddDirectorConversion2,688,270—Form 4
Jan 12, 2026Foley ToddDirectorConversion597,391—Form 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related